Logo for Pila Pharma

Pila Pharma Investor Relations Material

Latest events

Logo for Pila Pharma

Investor Update

Pila Pharma
Logo for Pila Pharma

Investor Update

4 Jul, 2025
Logo for Pila Pharma

Investor Update

3 Jul, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies

Latest reports from Pila Pharma

Access all reports
PILA PHARMA AB (publ) is a clinical stage pharmaceutical company developing XEN-D0501, a TRPV1 antagonist targeting the prevention and treatment of type 2 diabetes. The product candidate has completed two phase 2a clinical trials. Once it completes its ongoing phase 2b trial, PILA PHARMA AB (publ) is planning to initiate pivotal phase 3 study.